- Roche granted FDA Breakthrough Device Designation for blood test measuring Lp(a) – a key marker for hereditary cardiovascular risk
- FDA grants Breakthrough Therapy Designation to Roche’s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
- [Ad hoc announcement pursuant to Art. 53 LR] Roche reports positive Phase I results for its dual GLP-1/GIP receptor agonist CT-388 in people with obesity
- Roche announces FDA approval of one of the first HPV self-collection solutions in the U.S., expanding access and screening options to help eliminate cervical cancer
- [Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19
- [Ad hoc-Mitteilung gemäss Art. 53 KR] Verkäufe der Roche-Gruppe steigen im ersten Quartal um 2% (CER); beide Divisionen Pharma und Diagnostics wachsen im hohen einstelligen Bereich ohne COVID-19-Produkte
- FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer
- Roche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS
- [Ad hoc announcement pursuant to Art. 53 LR] Roche’s Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study
- Roche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimer's disease diagnosis
More ▼
Key statistics
As of last trade Roche Holding AG (RHO5:BRN) traded at 232.79, 8.83% above its 52-week low of 213.90, set on May 03, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 232.73 |
---|---|
High | 234.43 |
Low | 232.73 |
Bid | 229.00 |
Offer | 389.00 |
Previous close | 232.56 |
Average volume | 95.11 |
---|---|
Shares outstanding | 809.25m |
Free float | 731.55m |
P/E (TTM) | 16.23 |
Market cap | 190.25bn CHF |
EPS (TTM) | 14.30 CHF |
Annual div (ADY) | 9.60 CHF |
---|---|
Annual div yield (ADY) | 4.13% |
Div ex-date | Mar 14 2024 |
Div pay-date | Mar 18 2024 |
Data delayed at least 15 minutes, as of May 23 2024.
More ▼